Shanghai Yingrui Biopharma Co.,Ltd.
Home
About Us
ABOUT US
Corporate Culture
Products
APIs & Intermediates
PEG Derivatives
The others
Services
News
Company News
Industry Trends
Contact Us
NEWS CENTER
Hypertension medication enters a new era of long-acting efficacy
Hypertension is a major global risk factor for cardiovascular diseases, and antihypertensive drugs are chemical or biological agents used for the prevention and treatment of hypertension and related cardiovascular diseases. towards "precision targeting". It is reported that since 2026, various new mechanism drugs have achieved breakthroughs.
2026-06-03
2026
06-03
In May, the enthusiasm for mergers and acquisitions of domestic medical devices surged
Against the backdrop of normalized centralized procurement and accelerated liquidation during the industry downturn, consolidation is emerging as a core keyword in the evolution of China's medical device industry. It is reported that since May 2026, there have been multiple mergers and acquisitions in the Chinese medical device industry, involving companies such as Eastar Medical and Da An Gene
2026-05-19
05-19
The pharmaceutical industry is experiencing a round of structural recovery
The pharmaceutical industry is undergoing a round of structural recovery. Regarding the layout of the innovative drug sector, some analysts point out that, based on the research and judgments of multiple institutions, three main lines can be focused on: innovative drug leaders with global competitiveness, enterprises with technological advantages in specific niches, and supporting links in the industrial chain.
2026-04-30
04-30
In the first quarter, domestic pharmaceutical companies delivered impressive performance
Recently, pharmaceutical companies have been releasing their first-quarter earnings forecasts intensively. Overall, the innovative drug sector has emerged as the absolute mainstay, with over ten pharmaceutical companies reporting positive earnings forecasts, and three even showing a net profit increase of over 900%.
2026-04-17
04-17
The total amount of foreign licensing for innovative drugs in China has exceeded 60 billion US dollars
During the "15th Five-Year Plan" period, China's innovative drugs made a promising start in their global expansion. According to the National Medical Products Administration's new incomplete statistics, the total amount of foreign licensing fees for Chinese innovative drugs in the first three months of this year has exceeded US$60 billion.
2026-03-30
03-30
Anti-cancer cutting-edge TIL cell therapy has achieved multiple breakthroughs
TIL cell therapy, also known as tumor-infiltrating lymphocyte therapy, is an innovative cancer treatment method. After years of research and practice, this technology has gradually matured, bringing new hope to patients with advanced cancer.
2026-03-13
03-13
In 2026, multinational pharmaceutical companies intensively partnered
Just two months into 2026, the pharmaceutical industry has already witnessed a surge in collaborations between Chinese and multinational pharmaceutical companies.
2026-02-25
02-25
Domestic innovative drugs have ushered in another "blockbuster drug"
In the field of biomedicine, major products with annual sales exceeding US$1 billion are vividly referred to as "blockbuster" drugs. It is reported that China has welcomed another blockbuster drug, namely Carvykti (Cediranib Injection), a CAR-T product from the Chinese innovative drug company Legend Biologics.
2026-02-06
02-06
Antitumor drugs remain the focus of new drug approvals
In 2025, China's innovative drug sector delivered an impressive performance, with the National Medical Products Administration approving 76 innovative drugs for marketing throughout the year.
2026-01-20
01-20
The intelligent development of the pharmaceutical industry is accelerating once again!
Recently, eight departments including the Ministry of Industry and Information Technology
2026-01-08
01-08